Empagliflozin Protects HK-2 Cells from High Glucose-Mediated Injuries via a Mitochondrial Mechanism by Lee, Wen-chin et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Empagliflozin Protects HK-2 Cells from High Glucose-Mediated
Injuries via a Mitochondrial Mechanism
Citation for published version:
Lee, W, Chau, Y, Ng, H, Chen, C, Wang, P, Liou, C, Lin, T & Chen, J 2019, 'Empagliflozin Protects HK-2
Cells from High Glucose-Mediated Injuries via a Mitochondrial Mechanism', Cells, vol. 8, no. 9, pp. 1085.
https://doi.org/10.3390/cells8091085
Digital Object Identifier (DOI):
10.3390/cells8091085
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Cells
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. Nov. 2019
cells
Article
Empagliflozin Protects HK-2 Cells from High
Glucose-Mediated Injuries via a
Mitochondrial Mechanism
Wen-Chin Lee 1 , You-Ying Chau 2, Hwee-Yeong Ng 1, Chiu-Hua Chen 1, Pei-Wen Wang 3,
Chia-Wei Liou 4, Tsu-Kung Lin 4 and Jin-Bor Chen 1,*
1 Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and
Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan; leewenchin@gmail.com (W.-C.L.);
stan@cgmh.org.tw (H.-Y.N.); becky0917@cgmh.org.tw (C.-H.C.)
2 Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh,
Edinburgh EH16 4TJ, UK; You-Ying.Chau@ed.ac.uk
3 Division of Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and
Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan; wangpw@ms18.hinet.net
4 Department of Neurology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College
of Medicine, Kaohsiung 83301, Taiwan; cwliou@ms22.hinet.net (C.-W.L.); tklin@adm.cgmh.org.tw (T.-K.L.)
* Correspondence: chenjb1019@gmail.com; Tel.: +886-7-731-7123 (ext. 8306)
Received: 9 August 2019; Accepted: 13 September 2019; Published: 14 September 2019


Abstract: Empagliflozin is known to retard the progression of kidney disease in diabetic patients.
However, the underlying mechanism is incompletely understood. High glucose induces oxidative
stress in renal tubules, eventually leading to mitochondrial damage. Here, we investigated
whether empagliflozin exhibits protective functions in renal tubules via a mitochondrial mechanism.
We used human proximal tubular cell (PTC) line HK-2 and employed western blotting, terminal
deoxynucleotidyl transferase dUTP nick end labelling assay, fluorescence staining, flow cytometry,
and enzyme-linked immunosorbent assay to investigate the impact of high glucose and empagliflozin
on cellular apoptosis, mitochondrial morphology, and functions including mitochondrial membrane
potential (MMP), reactive oxygen species (ROS) production, and adenosine triphosphate (ATP)
generation. We found that PTCs were susceptible to high glucose-induced mitochondrial
fragmentation, and empagliflozin ameliorated this effect via the regulation of mitochondrial
fission (FIS1 and DRP1) and fusion (MFN1 and MFN2) proteins. Empagliflozin reduced the high
glucose-induced cellular apoptosis and improved mitochondrial functions by restoring mitochondrial
ROS production, MMP, and ATP generation. Our results suggest that empagliflozin may protect renal
PTCs from high glucose-mediated injuries through a mitochondrial mechanism. This could be one of
the novel mechanisms explaining the benefits demonstrated in EMPA-REG OUTCOME trial.
Keywords: empagliflozin; mitochondria; proximal tubular cell; diabetic kidney disease
1. Introduction
Diabetic kidney disease (DKD) affects approximately 40% of patients with diabetes and has
emerged as a leading cause of chronic kidney disease worldwide [1–3]. Empagliflozin, one of
the sodium-glucose cotransporter 2 (SGLT2) inhibitors, has recently been reported to retard the
progression of DKD in EMPA-REG OUTCOME trial [4]. Animal studies have shown that empagliflozin
improves renal functions [5] and is associated with reduced hyperfiltration, albuminuria [6], and
ameliorated pathology [7]. However, the mechanisms underlying these effects remain largely unknown.
The proposed mechanisms include weight loss, natriuresis, and renal tubuloglomerular feedback [8].
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The production of reactive oxygen species (ROS) is increased in diabetes [9], resulting in
mitochondrial insult and altered mitochondrial genetics and functions. This mitochondriopathy
has emerged as a crucial phenomenon in DKD, owing to known changes in the mitochondrial DNA
copy number in the leukocytes [10], altered expression of mitochondrial proteins in DKD patient
kidneys, and enlarged mitochondria in the renal proximal tubules of animal models and human renal
biopsy tissues [11].
Oxidative stress-mediated mitochondrial injuries result in cellular dysfunction and even death
via apoptotic pathways. The mitochondrial morphology is shown to be altered in response to these
processes. Mitochondrial morphological dynamics are determined by the balance between two
opposing processes, namely, fission and fusion. The key proteins involved in mitochondrial fusion
include mitofusin 1 (MFN1) and mitofusin 2 (MFN2) [12,13], while dynamin-related protein-1 (DRP1)
and mitochondrial fission 1 protein (FIS1) are associated with the mitochondrial fission. High glucose
induces mitochondrial fragmentation and cellular apoptosis in renal proximal tubules [14]. As
renal proximal tubular cells (PTCs) are the direct site of action for SGLT2 inhibitors, here we used
human kidney PTCs to investigate whether SGLT2 inhibitors offer direct renal protection via a
mitochondrial mechanism.
2. Materials and Methods
2.1. Cell Culture and Chemicals
HK-2 cells (ATCC CRL-2190, BCRC 60097, Taiwan) were incubated in culture plates without
filters in a humidified atmosphere with 5% CO2 at 37 ◦C. The culture medium comprised of 500 mL of
keratinocyte medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 25 mL fetal bovine
serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and 5 mL penicillin/streptomycin
(Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). All chemicals were purchased from
Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated. The concentrations of empagliflozin
(Boehringer Ingelheim, Ingelheim, Germany) used were based on the published report and preclinical
studies performed at Boehringer Ingelheim [15,16].
2.2. Cell Viability Assay
Crystal violet assay was performed to examine the effect of empagliflozin on cell viability.
Cell viability was measured using previously described protocols [14]. Cells were seeded in 96-well
plates (5 × 103 cells/well). After an overnight incubation, cells were treated with high (30 mM) or
normal (5 mM) concentration of glucose for 24 h. [15]. Cells were treated with 0.5% crystal violet
reagent in phosphate-buffered saline (PBS) for 2 h at 37 ◦C. The cells were washed 10 times with
PBS and air-dried, followed by incubation with 100 mL of dimethyl sulfoxide for 1–2 h for complete
dissolution of the dye. The absorbance of the reaction product was measured at 570 nm using a
microplate reader.
2.3. Western Blot Analysis
Cells were seeded at a density of 3 × 105 cells/well in a six-well plate. After an overnight
incubation, cells were incubated in normal or high glucose medium. Western blot analysis was carried
out as previously described [17]. In brief, cell pellets were homogenized in a buffer and centrifuged
at 14,000× g. Protein (40 µg) from the supernatant of each sample was separated with sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene
difluoride membranes by electrophoresis. The membranes were blocked in TBST buffer for 1 h at room
temperature. The blots were probed with primary anti-MFN1 (sc-100561, Santa Cruz Biotechnology, Inc),
anti-MFN2 (sc-100560, Santa Cruz Biotechnology, Inc), anti-DRP1 (sc-101270, Santa Cruz Biotechnology,
Inc), and anti-FIS1 (GTX111010, GeneTex, Inc) antibodies, followed by incubation with secondary
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antibodies at an appropriate dilution. The blots were visualized with the Western Lightning Plus-ECL
(PerkinElmer, Waltham, MA, USA).
2.4. Mitochondrial Fragmentation Index
Mitochondrial morphology was assayed as previously described with some modifications [14,18].
Briefly, mitochondria were stained by the fluorescent dye Mitotracker red (Invitrogen, Life Technologies,
Carlsbad, CA, USA) and observed under a fluorescence microscope (Olympus BX-UCDB-2; Olympus
Corporation, Tokyo, Japan). Mitochondrial morphology was scored in a blinded and independent
manner by two experienced technicians. Mitochondria with punctated or fragmented patterns
were termed as the fission type. The fission rate (%) was defined as the percentage of fission type
mitochondrion among all counted mitochondria, i.e., fission events/total (fission + intermediate +
fusion types) × 100.
2.5. Cellular Apoptotic Assay
In the terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay, HK-2 cells
incubated for 24 h in the presence or absence of empagliflozin were fixed in 4% paraformaldehyde
and treated with a blocking solution (10% FBS in PBS) for 30 min at 25 ◦C. Cells were permeabilized
with 0.1% (v/v) Triton X-100 in PBS, followed by incubation with the TUNEL reaction mixture (Roche,
Mannheim, Germany) for 1 h at 37 ◦C. After the treatment, the cells were observed under a fluorescence
microscope (Olympus BX-51; Olympus Corporation, Tokyo, Japan).
2.6. Measurement of Mitochondrial Membrane Potential (MMP)
Rhodamine 123 (Invitrogen, Life Technologies, Carlsbad, CA, USA) was used to measure MMP,
as previously described [19]. Briefly, 2 × 105 cells were plated in each well of a six-well plate and
allowed to attach for 16–18 h. After treatment for 48 h, the cells were harvested with trypsin, washed
with PBS, and resuspended in 200 ng/mL of Rhodamine 123. After incubation for 30 min at 37 ◦C, the
cells were washed thrice and resuspended in 500 mL of PBS. Cytofluorimetric analysis was performed
using a BD Biosciences FACScan system.
2.7. Quantification of Cellular and Mitochondrial ROS
Cellular ROS level was detected using 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA)
as previously described [20]. Briefly, 2 × 105 cells were incubated with appropriate concentrations
of glucose and empagliflozin for 24 h. The cells were washed twice with PBS and incubated with
10 µM DCFH-DA (Molecular Probes, Life Technologies, Carlsbad, CA, USA) for 30 min at 37 ◦C.
Cells were harvested with trypsin/ethylenediaminetetraacetic acid (EDTA), centrifuged at 200× g for
5 min, and resuspended in 0.5 mL of PBS. Cellular ROS level was measured by flow cytometry using
a fluorescence-activated cell scanner FACScan machine (BD Biosciences Inc., San Jose, CA, USA).
The mean fluorescence intensity (MFI) for each sample was calculated using the CellQuest software.
Mitochondrial ROS level was calculated using MitoSOX Red (Invitrogen, Life Technologies, Carlsbad,
CA, USA). Briefly, 2 × 105 cells were plated in each well of six-well plates and allowed to attach for
16–18 h. After being treated with drugs for 24 h, the cells were harvested by trypsin treatment, washed
in PBS, and resuspended in 5 µM MitoSOX red. After incubation for 30 min at 37 ◦C, the cells were
washed thrice and resuspended in 500 µL of PBS. Cytofluorimetric analysis data were similar to those
of cellular ROS quantitation.
2.8. Measurement of ATP Generation
ATP content was colorimetrically determined with the ATP Colorimetric/Fluorometric Assay kit
(BioVision, Milpitas, CA, USA) following the manufacturer’s instructions. Briefly, 1 × 106 cells were
maintained in a T75 flask overnight. Treatment groups included 5 mM glucose, 30 mM glucose, 30 mM
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glucose + 100 nM empagliflozin, and 30 mM glucose + 500 nM empagliflozin groups. After overnight
treatment, the cells were harvested, collected by centrifugation at 200× g for 3 min, washed with PBS,
and lysed in 100 µL ATP assay buffer. The samples or standards (50 µL per well) and the reaction
mix (50 µL per well) were added to a 96-well plate and incubated for 30 min. Then, absorbance was
measured at 570 nm using an ELISA reader Quant (BioTek Instruments Inc., Winooski, VT, USA)
2.9. Statistical Analysis
All experiments were repeated at least three times. The quantitative data are presented as mean ±
standard error of the mean (SEM). Statistical analyses were performed using IBM SPSS Statistics for
Windows, Version 19.0. (IBM Corp., Armonk, New York, NY, USA). Comparisons between multiple
groups were carried out using one-way analysis of variance (ANOVA). Pair-wise comparisons were
performed using the t-test. A value of P < 0.05 was considered significant.
3. Results
3.1. Empagliflozin Exerts Insignificant Effects on Cell Viability
The viability of HK-2 cells treated with the indicated concentrations of glucose and empagliflozin
is shown in Figure 1. We tested empagliflozin at concentrations of 100, 500, 1000, and 2000 nM
under normal (5 mM) and high glucose (30 mM) conditions. Treatment with the fixed concentration
of acetonitrile, which was used as the solvent for empagliflozin, was considered as vehicle control.
Empagliflozin did not affect cellular viability. In comparison with the normal glucose condition,
high glucose condition caused a 12% reduction in cell viability (Figure 1). In addition to demonstrating
that empagliflozin exerts insignificant effects on cell viability, we performed validation experiments
including glucose uptake and RNA interference to silence SGLT2. These validation experiments were
to confirm the primary effects of empagliflozin on HK-2 cells and to support that our pharmacology
experiment results were specifically due to SGLT2 inhibition (Supplementary Material).
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Figure 1. E pagliflozin has no negative effects on the viability of K-2 cells. Cell viability as
easured with crystal violet assay and the absorbance was analyzed at 570 n using a icroplate
reader. Data were obtained from three independent experiments and are expressed as mean ± SE .
Only high glucose (30 mM) treatment led to a decrease in cell viability. * P < 0.05 versus the normal
glucose (5 mM) treatment group. Glu, glucose; Empa, empagliflozin.
3.2. Empagliflozin Rescues High Glucose-Induced Mitochondrial Fragmentation in Human PTCs
Earlier, we have demonstrated the effect of high glucose on mitochondrial fragmentation in human
PTCs [14]. We, therefore, investigated whether empagliflozin rescues this effect. Figure 2A–D shows
the morphological features of mitochondria from the four treatment groups. Magnified images of
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indexed mitochondria in each treatment group are shown in Figure 2E–H. We found that HK-2 cells
were susceptible to high glucose-induced mitochondrial fragmentation, and empagliflozin could rescue
mitochondrial fragmentation. To quantitatively analyze the process of mitochondrial fragmentation,
we calculated the mitochondrial fission rate in each treatment group. High glucose (30 mM) condition
led to a four-times higher fission rate in HK-2 cells than the normal glucose condition. In the presence
of high glucose, empagliflozin at either 100 or 500 nM concentration could reduce the mitochondrial
fission rate to a level comparable to that reported under normal glucose condition (Figure 2I).
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Figure 2. Empagliflozin rescues high glucose-induced mitochondrial fragmentation in human PTCs.
HK-2 cells were cultured in 5 mM glucose (A), 30 mM glucose (B), 30 mM glucose with 100 nM
empagliflozin (C), and 30 mM glucose with 500 nM empagliflozin (D). Mitochondria were stained
with Mitotracker red. Magnified images of indexed mitochondria (arrow) in each treatment group are
shown in (E–H). (I) The mitochondrial fission rate was higher in high glucose condition. Empagliflozin
rescued this effect. Data were obtained from three independent experiments and are expressed as mean
± SEM. * P < 0.05, ** P < 0.001.
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3.3. Impacts of High Glucose and Empagliflozin on the Expression of Mitochondrial Fusion/Fission Proteins
Western blot analysis (Figure 3A) revealed the high glucose-induced downregulation in the
expression of fusion proteins (i.e., MFN1 and MFN2, Figure 3B,C). Empagliflozin could reverse the high
glucose-induced downregulation of MFN1 and MFN2 expression at 500 and 100 nM concentration,
respectively (Figure 3B,C). High glucose failed to cause any changes in the expression of fission proteins
(i.e., DRP1 and FIS1, Figure 3D,E). In the presence of high glucose, empagliflozin could downregulate
the expression of DRP1 at 100 nM concentration. Similar effects were observed on FIS1 expression in
the presence of 500 nM empagliflozin (Figure 3D,E). As mitochondrial morphology is controlled by
the balance between fusion/fission proteins, the results shown in Figure 3 support the observation
illustrated in Figure 2.
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Figure 3. Impact of empagliflozin on high glucose-induced alterations in the expression levels of
mitochondrial fusion/fission proteins. (A–E) The expression of MFN1, MFN2, DRP1, and FIS1 was
analyzed with western blotting and normalized to the level of β-actin. Data are expressed as mean ±
SEM. * P < 0.05, ** P < 0.001.
3.4. Empagliflozin Reduces the High Glucose-Induced Cellular Apoptosis of HK-2 Cells
Compared to the normal glucose condition (Figure 4A), high glucose condition induced a marked
increase in the level of cellular apoptosis (Figure 4B). Empagliflozin at 100 and 500 nM concentrations
offered effective protection against high glucose-induced apoptosis (Figure 4C and 4D). Quantitative
analysis of TUNEL assay result showed that high glucose markedly induced apoptosis and that
empagliflozin could ameliorate this effect (Figure 4E).
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3.5. Empagliflozin Improves Mitochondrial Function in High Glucose-Treated HK-2 Cells
We examined mitochondrial function of HK-2 cells by analyzing cellular (Figure 5A) and
mitochondrial ROS production (Figure 5B), MMP (Figure 5C), and ATP generation (Figure 5D).
High glucose increased both cellular and mitochondrial ROS levels. Empagliflozin at 500 nM could
reduce the cellular ROS level, although 100 nM empagliflozin was not sufficiently effective (Figure 5A).
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Empagliflozin at 100 and 500 nM concentrations could maintain the mitochondrial ROS production level
(Figure 5B). High glucose caused a decrease in MMP and this effect was ameliorated by empagliflozin
at 500 nM concentration (Figure 5C). Empagliflozin at a concentration of either 100 or 500 nM was
able to increase the level of ATP in HK-2 cells (Figure 5D). Taken together, the results of mitochondrial
functional assays show that empagliflozin at 500 nM concentration produced healthier mitochondria
to combat the stress induced by high glucose.
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(A) Cellular ROS production, (B) mitochondrial ROS production, (C) MMP, and (D) ATP generation in
the four treatment groups. Data were obtained from three independent experiments and are expressed
as mean ± SEM. * P < 0.05, ** P < 0.001.
4. Discussion
Complimentary to the traditional ‘glomerulocentric’ perspective of diabetic nephropathy,
the understanding of the pathophysiological perturbations in the tubules is essential for the successful
management of DKD. In the diabetic milieu, increased energy demands and a decreased perfusion result
in tubular hypoxia. This phenomenon may drive the development of tubular atrophy and interstitial
fibrosis in a vicious cycle that worsens the clinical course of DKD [21]. At the subcellular level, the
mitochondrion of diabetic proximal tubules is the key organelle that modulates its propensity to hypoxic
injury and oxidative stress. Studies on subcellular levels often unravel the underlying mechanisms
that clinical trials may not reach. Here, we investigated the subcellular mechanisms underlying the
protective effect of empagliflozin from high glucose-mediated injuries on PTCs. As oxidative stress
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plays pathologic roles in diabetic kidneys [22–24] and empagliflozin may reduce this effect [25,26], we
analyzed the direct effects of empagliflozin on the mitochondria of PTCs.
In PTCs, high glucose treatment induces mitochondrial fragmentation and cellular
apoptosis [14,27]. Our results showed that empagliflozin protected PTCs from high glucose-induced
injuries through the modulation of the expression of mitochondrial fusion and fission proteins. We
demonstrate that empagliflozin could rescue high glucose-induced mitochondrial fragmentation.
At the protein level, high glucose condition significantly downregulated the expression levels of
both mitochondrial fusion proteins, while empagliflozin treatment rescued this effect by enhancing
the expression levels of both mitochondrial fusion proteins. Although not significant, high glucose
seemed to cause an upregulation in the expression levels of mitochondrial fission proteins, which
were significantly downregulated by empagliflozin. In line with the proposed protective mechanism
in a different cellular aspect [28], empagliflozin might make mitochondria more resistant to high
glucose-driven fragmentation by upregulating the expression of fusion proteins and downregulating
the levels of fission proteins. This protective mechanism may explain why empagliflozin protected
PTCs from high glucose-induced mitochondrial fragmentation and cellular apoptosis.
In addition to shaping the mitochondrial morphology, empagliflozin could also improve
mitochondrial functions. Mitochondrial dysfunction has been reported in experimental diabetic
animal and cellular models [29–31]. These disturbances in mitochondrial functions may result
in the excessive accumulation of cellular ROS [30,32], ATP depletion [33], and MMP reduction [30].
Our results confirm these observations in response to high glucose-induced mitochondrial dysfunctions
in PTCs and demonstrate that empagliflozin could ameliorate these effects. In DKD, ROS is produced
from various organelles within the cell, including the mitochondrion, endoplasmic reticulum, and
the enzyme systems such as Nox. ROS underproduction may be indicative of the mitochondrial
dysfunction. Steady-state levels of ROS are involved in normal cellular signaling, whereas excessive
ROS production leads to cellular dysfunction [34]. Our results demonstrate that empagliflozin reduced
the cellular ROS level while maintaining the mitochondrial ROS production.
The mitochondrion has been recognized as a crucial target for DKD treatment [35,36]. Several
mitochondrion-targeted agents, including MitoQ [37], Ebselen [38], Bendavia [39], and MitoTEMPO [40],
have been reported. Although the molecular pathways underlying the empagliflozin-mediated increase
in mitochondrial fitness are not completely understood, our results indicated that empagliflozin could
serve as a mitochondrion-targeting agent. Proximal tubules, the direct site of action of empagliflozin,
emerge as a novel therapeutic target for DKD [21]. This study revealed a novel mechanism explaining
the renal benefits of empagliflozin, as demonstrated in the EMPA-REG OUTCOME trial, and this
warrants future studies to identify its role in diabetic tubulopathy.
5. Conclusions
In conclusion, we demonstrated that empagliflozin treatment improves mitochondrial
performance in HK-2 cells, as reflected from their morphologies and functions, to overcome high
glucose-induced injuries.
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